First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the larger and more established fund, having launched in 2001 and managing $9.6 billion in assets under management First Trust NYSE Arca Biotechnology Index Fund has achieved a higher total return over both one-year and five-year horizons
A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.
Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 997 | $200,217 | $245,810.35 | $45,593.35 | 22.77% |
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 201 | $34,241.29 | $49,556.55 | $15,315.26 | 44.73% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 6,990 | $1.21M | $1.72M | $511,302.54 | 42.19% |
| PP Philip Perry FLAGSTAR ADVISORS Inc. | 3,649 | $509,577.52 | $897,654 | $388,076.48 | 76.16% |
| RR rosemary richard WCG Wealth Advisors LLC | 74,342 | $14.93M | $18.29M | $3.36M | 22.5% |
| ARCA Exchange | US Country |
This financial entity operates as an investment fund focusing predominantly on the biotechnology sector. It is structured to track the performance of 30 leading biotechnology companies, employing a strategic approach by allocating at least 90% of its net assets (this includes any borrowed investments) directly into the securities that form the basis of its targeted index. The index itself is constructed on an equal-dollar weighted basis, ensuring that each company within the index has an equal influence on the fund's overall performance. This method is designed to provide investors with a diversified exposure to the biotechnology industry, capturing the growth and innovation within this sector.
The primary offering of this fund revolves around equity investments in biotechnology companies. By focusing on 30 leading firms within the sector, the fund aims to tap into the growth potential of biotechnological advancements and innovations. This approach allows investors to gain exposure to a wide array of companies developing novel therapies, medical devices, and diagnostic tools, among other contributions to the healthcare sector.